|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, April 23, 2016 ) The Parkinson Disease Therapeutics Market Report shows that the global Parkinson's Disease (PD) prevalence was estimated at 16.1 million in 2011, and after Alzheimer's disease it is the second most common neuro-degenerative disease worldwide. Parkinson's Disease (PD) is a progressive disease and, although not fatal, it can develop severe symptoms and complications that significantly impact upon the patient's quality of life. Symptoms for each stage can be categorized into early, moderate and advanced stages. Major motor symptoms of Parkinson's Disease (PD) include tremors and difficulty walking. Parkinson's Disease (PD) also gives rise to non-motor symptoms, such as dementia, depression, hallucinations and loss of taste and smell. There are several different drug classes available to relieve Parkinson's Disease (PD) symptoms. The aim is for treatments to increase dopamine levels, which is substantially diminished in brains affected by Parkinson's Disease (PD).
Other Key Points in Report:
-A brief introduction to Parkinson's Disease (PD), including pathogenesis, disease staging, diagnosis and treatment algorithms
-Comprehensive analysis of the drugs available for the treatment of PD, covering their safety, efficacy, treatment patterns, and strengths/weaknesses, as well as a heat map comparing drugs in terms of safety and efficacy
-Comprehensive analysis of the pipeline for Parkinson's Disease (PD) therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period, on the basis of Phase distribution, molecule type and molecular target
-Additional thorough analysis of pipeline drug clinical trials by Phase, molecule type, trial size, trial duration, and program failure rate for each molecule type and mechanism of action
-Multi-scenario market forecast data to 2021, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across the key developed markets of the US, Canada, Japan, Germany, the UK, France, Italy and Spain
Inquire before Buying Report@ http://www.reportsweb.com/inquiry&RW0001170047/buying
Table of Content: An Overview
2 Introduction 9
2.1 Disease Introduction 9
2.2 Symptoms 9
2.3 Etiology 10
2.3.1 Genetic Factors 10
2.3.2 Environmental Factors 11
2.3.3 Aging 11
2.4 Pathophysiology 12
2.5 Epidemiology 13
2.6 Disease Stages 14
2.7 Co-morbidities and Complications 15
2.8 Diagnosis 15
2.9 Assessment of Disease Severity 16
2.9.1 Hoehn and Yahr scale 16
2.9.2 Unified Parkinson's Disease Rating Scale 16
2.10 Treatment 17
2.10.1 Pharmacological Therapies 18
2.10.2 Non-pharmacological Treatments 20
2.11 Treatment Algorithm 21
2.11.1 Early Parkinson's Disease 21
2.11.2 Advanced Parkinson's Disease 22
Ask for Discount on Report @ http://www.reportsweb.com/inquiry&RW0001170047/discount
3 Marketed Products 25
3.1 Overview 25
3.1.1 Dopamine Replacement Therapies 25
3.1.2 MAO-B Inhibitors 28
3.1.3 Dopamine Agonists 30
3.1.4 COMT Inhibitors 35
3.1.5 Other Drugs Targeting Non-motor Symptoms of PD 39
3.2 Comparative Efficacy and Safety 40
4 Pipeline for Parkinson's Disease 44
4.1 Overview 44
4.2 Pipeline Distribution by Mechanism of Action/Molecular Target 46
4.3 Clinical Trials 49
4.3.1 Failure Rate 49
4.3.2 Clinical Trial Duration 51
4.3.3 Clinical Trial Size 53
4.3.4 Comparison of Average Trial Metrics by Phase and Mechanism of Action 55
4.4 Promising Pipeline Molecules 56
4.4.1 Opicapone-Bial 56
4.4.2 Nuplazid (pimavanserin)-Acadia Pharmaceuticals 58
4.4.3 Nurelin (Amantadine Hydrochloride Extended-Release)-Adamas Pharmaceuticals 59
4.4.4 Tozadenant-Biotie Therapies 60
4.4.5 APL-130277 (apomorphine hydrochloride)-Cynapsus Therapeutics 61
4.4.6 P2B001 (pramipexole dihydrochloride + rasagiline mesylate)-Pharma Two B 63
4.4.7 DM-1992 (levodopa + carbidopa extended release)-Depomed 63
Purchase Complete Report @ http://www.reportsweb.com/buy&RW0001170047/buy/4995
About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
